Amalgamated Financial’s Krystal Biotech KRYS Stock Holding History

Amalgamated Financial’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$162K	Buy	+2,437	New	+$152K	﹤0.01%	1980

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Amalgamated Financial's KRYS Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Krystal Biotech (KRYS) in Q1 2022: 2,437 shares worth $162K. The stake represents ﹤0.01% of the portfolio and ranks #1980 among its holdings.

135 funds tracked by Wall St. Rank hold KRYS as of Q1 2022.

Amalgamated Financial held 2,437 shares of Krystal Biotech worth $162K as of Q1 2022.
Krystal Biotech was a new Amalgamated Financial position in Q1 2022.
Krystal Biotech made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1980 holding.
135 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.